In November 2026, the FDA sent out a Drug Safety Communication, “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition" that some drug safety observers would say was overdue. For example, this … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Cancer and Disease Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Lawsuits
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Our "Recent Articles" Archives
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent Articles
Andexxa Side Effects DVT and PE; Andexxa Legal Compensation Claims
Case reports of serious Andexxa side effects, deep vein thrombosis (DVT) and pulmonary embolism (PE), resulted in the FDA starting a drug safety investigation in November 2024. The issue was whether there was an apparent increased rate of Andexxa-related blood clots, which can lead to DVT and/or PE, … More
‘Malignant Mesothelioma Mortality in Women” MMWR Report Evaluated
On May 13, 2022, there was a published report in the MMWR titled “Malignant Mesothelioma Mortality in Women – United States, 1999-2020” (Mazurek et al., 2022). The authors of this MMWR relied upon the National Vital Statistic System’s Multiple Cause of Death (MCD) records to analyze trends for this … More
No NAION Warnings: Ozempic, Wegovy, Mounjaro, and Zepbound
Despite an increasing number of medical journal articles about non-arteritic anterior ischemic optic neuropathy NAION being linked to Ozempic, Wegovy, Mounjaro, and Zepbound, there are still no NAION warnings in the current drug labels here in the United States for these popular drugs. Here are a … More
Mounjaro and Ozempic Lawsuits for NAION “Eye Stroke” Vision Loss Explained
An increasing number of people are filing Mounjaro and Ozempic lawsuits for NAION "eye stroke" vision loss in 2026, and that trend is expected to continue in 2027. Here is a 10-point "explainer" to give you a better understanding of why these people are seeking legal compensation for losing their … More
Tavneos Liver Drug Injury Lawsuits: New Medical Evidence in 2026
In this article, we present new evidence from medical registry data that further supports Tavneos liver drug injury lawsuits. We have been investigating possible Tavneos liver injury cases involving Tavneos drug-induced liver injury (DILI) and Tavneos-related vanishing bile duct syndrome (VBDS) … More